A multi-society Delphi consensus statement on new fatty liver disease nomenclature.

[1]  V. Wong,et al.  Stigma in NAFLD and NASH: a global survey of patients and providers , 2023, Journal of Hepatology.

[2]  P. Newsome,et al.  Diagnosis of fatty liver in children should occur in parallel to investigation for other causes of liver disease. , 2023, The lancet. Gastroenterology & hepatology.

[3]  B. Neuschwander‐Tetri,et al.  AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. , 2023, Hepatology.

[4]  J. Lazarus,et al.  Knowledge of liver fibrosis stage among adults with NAFLD/NASH improves adherence to lifestyle changes , 2022, Liver international (Print).

[5]  M. Manns,et al.  The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality , 2021, The Lancet.

[6]  A. Sanyal,et al.  Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. , 2021, Gastroenterology.

[7]  M. Friedrich-Rust,et al.  Easl Clinical Practice Guidelines (Cpgs) On Non-Invasive Tests For Evaluation Of Liver Disease Severity And Prognosis- 2020 Update. , 2021, Journal of hepatology.

[8]  Sascha L. Schmidt,et al.  Preparing, conducting, and analyzing Delphi surveys: Cross-disciplinary practices, new directions, and advancements , 2021, MethodsX.

[9]  T. Luedde,et al.  Diagnosis and management of secondary causes of steatohepatitis. , 2021, Journal of hepatology.

[10]  V. Wong,et al.  Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. , 2021, The lancet. Gastroenterology & hepatology.

[11]  N. Sheron,et al.  "Dual aetiology fatty liver disease": a recently proposed term associated with potential pitfalls. , 2020, Journal of hepatology.

[12]  M. Allison,et al.  The European NAFLD registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. , 2020, Contemporary clinical trials.

[13]  V. Wong,et al.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease , 2020, Hepatology International.

[14]  J. George,et al.  Reply to: correspondence regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement": Bringing evidence to the NAFLD-MAFLD debate. , 2020, Journal of Hepatology.

[15]  A. Sanyal,et al.  The times they are a-changin' (for NAFLD as well). , 2020, Journal of hepatology.

[16]  Z. Goodman,et al.  From NAFLD to MAFLD: Implications of a Premature Change in Terminology , 2020, Hepatology.

[17]  V. Wong,et al.  A new definition for metabolic associated fatty liver disease: an international expert consensus statement. , 2020, Journal of hepatology.

[18]  A. Sanyal,et al.  MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. , 2020, Gastroenterology.

[19]  N. Bhala,et al.  Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. , 2020, Gastroenterology.

[20]  F. Tacke,et al.  Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD , 2019, Hepatology.

[21]  M. Allison,et al.  Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. , 2019, Gastroenterology.

[22]  B. Neuschwander‐Tetri,et al.  Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science , 2017, Hepatology.

[23]  N. Robinson,et al.  Developing An Acupuncture Protocol for Treating Phantom Limb Pain: A Delphi Consensus Study , 2015, Acupuncture in Medicine.

[24]  Joan Tordjman,et al.  Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients , 2012, Hepatology.

[25]  Vincent Wai-Sun Wong,et al.  Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography , 2011, Gut.

[26]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[27]  Jane B Shofer,et al.  Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. , 2004, Diabetes.

[28]  P. Bedossa,et al.  Risk factors of fibrosis in alcohol‐induced liver disease , 2002, Hepatology.

[29]  E. Brunt.  Nonalcoholic steatohepatitis (NASH): further expansion of this clinical entity? , 1999, Liver.

[30]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[31]  F. Capron,et al.  Excess weight risk factor for alcoholic liver disease , 1997, Hepatology.

[32]  J. Ludwig,et al.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.